IMIO raises $12m seed led by Sofinnova Partners to turn crop residue into nutrient credit
Sofinnova Partners leads a $12 million seed round for IMIO, whose Re-Gen residue treatment lifted corn yields by 11.9 bushels per acre in trials.
IMIO, a US manufacturer of agricultural biologicals, announced a $12 million seed round on 20 October 2026. Sofinnova Partners led, with Chipotle's venture fund Cultivate Next, Starshot Capital, Grow Together Salinas, Earth Foundry and Serra Ventures taking part. AgFunderNews puts total funding to date at $16.5 million. The company was founded in 2019 by Charles Smith, founder and chief executive, and has moved from Vermont to Chicago, Illinois, where the proceeds will pay for a headquarters, laboratory and biomanufacturing site that AgNavigator reports is due for completion in the second quarter of 2027.
The product is Re-Gen, a granular treatment applied to crop residue rather than to soil, sold as Re-Gen for Row Crops and Re-Gen for Produce and registered as a biostimulant in all 50 US states. The microbes are naturally occurring and non-GM, grown separately, freeze-dried and then blended in set ratios into a powder with a shelf life of twelve months or more. IMIO uses lyophilisation rather than heat-based spray drying, which it says would kill the lignin-degrading fungi that do the work of breaking residue down. Application typically falls in spring, around planting.
The evidence behind it comes from more than 10,000 acres of Midwest trials. Corn plots showed an average yield increase of 11.9 bushels per acre, with individual results ranging from 5.32 to 22.67 bushels. The company puts nutrient credits at up to $120 per acre in row crops and tillage savings at up to $120 per acre in produce. It has sold to more than 100 customers, and the formulations are patent pending.
The pitch is aimed at the category's credibility problem rather than at a yield claim. CropLife's 2026 Biologicals Survey found that 39 per cent of ag retailers and advisers named trust as the main barrier to adoption, and Smith told AgFunderNews that consistency has been the biggest challenge when it comes to wide scale adoption and trust in biologicals. In the funding announcement he said: “Farmers deserve trustworthy partners and products.” Guillaume Baxter, partner at Sofinnova Partners, put the case agronomically, saying that crop residue “is a major challenge for farmers, affecting soil productivity and driving up input costs”.
Why it matters for AgTech founders: the instructive part of this round is not the microbes, it is where the product sits on the farm's accounts. Residue is a cost line almost everywhere, so a treatment that converts it into a nutrient credit argues against an expense the grower already carries rather than against a yield promise that only settles at harvest. That is a shorter argument to win, and it is visible in the acreage. The second lesson is formulation as the moat. Non-GM soil organisms are something many laboratories can isolate, and what IMIO is actually funding in Chicago is the freeze-drying and blending line, because the difference that matters is whether the organisms are still alive when the spreader goes past. Founders who treat manufacturing as a later-stage problem usually meet it again as a trust problem, and the CropLife figure is the bill the whole category is paying for that. Third, read the cap table. A European life sciences investor leads and a restaurant group's venture arm sits beside it, which is the shape of a round where the downstream buyer is underwriting the agronomy. If your product changes what a food company can say about its supply chain, that company's balance sheet belongs on your fundraising map well before an input industry strategic does.
IMIO raises $12m seed led by Sofinnova Partners to turn crop residue into nutrient credit
Chipotle's venture fund joins the round as the Chicago manufacturer takes its freeze-dried residue microbes from Midwest field trials to commercial scale.
IMIO, a US manufacturer of agricultural biologicals, announced a $12 million seed round on 20 October 2026. Sofinnova Partners led, with Chipotle's venture fund Cultivate Next, Starshot Capital, Grow Together Salinas, Earth Foundry and Serra Ventures taking part. AgFunderNews puts total funding to date at $16.5 million. The company was founded in 2019 by Charles Smith, founder and chief executive, and has moved from Vermont to Chicago, Illinois, where the proceeds will pay for a headquarters, laboratory and biomanufacturing site that AgNavigator reports is due for completion in the second quarter of 2027.
The product is Re-Gen, a granular treatment applied to crop residue rather than to soil, sold as Re-Gen for Row Crops and Re-Gen for Produce and registered as a biostimulant in all 50 US states. The microbes are naturally occurring and non-GM, grown separately, freeze-dried and then blended in set ratios into a powder with a shelf life of twelve months or more. IMIO uses lyophilisation rather than heat-based spray drying, which it says would kill the lignin-degrading fungi that do the work of breaking residue down. Application typically falls in spring, around planting.
The evidence behind it comes from more than 10,000 acres of Midwest trials. Corn plots showed an average yield increase of 11.9 bushels per acre, with individual results ranging from 5.32 to 22.67 bushels. The company puts nutrient credits at up to $120 per acre in row crops and tillage savings at up to $120 per acre in produce. It has sold to more than 100 customers, and the formulations are patent pending.
The pitch is aimed at the category's credibility problem rather than at a yield claim. CropLife's 2026 Biologicals Survey found that 39 per cent of ag retailers and advisers named trust as the main barrier to adoption, and Smith told AgFunderNews that consistency has been the biggest challenge when it comes to wide scale adoption and trust in biologicals. In the funding announcement he said: “Farmers deserve trustworthy partners and products.” Guillaume Baxter, partner at Sofinnova Partners, put the case agronomically, saying that crop residue “is a major challenge for farmers, affecting soil productivity and driving up input costs”.
Why it matters for AgTech founders: the instructive part of this round is not the microbes, it is where the product sits on the farm's accounts. Residue is a cost line almost everywhere, so a treatment that converts it into a nutrient credit argues against an expense the grower already carries rather than against a yield promise that only settles at harvest. That is a shorter argument to win, and it is visible in the acreage. The second lesson is formulation as the moat. Non-GM soil organisms are something many laboratories can isolate, and what IMIO is actually funding in Chicago is the freeze-drying and blending line, because the difference that matters is whether the organisms are still alive when the spreader goes past. Founders who treat manufacturing as a later-stage problem usually meet it again as a trust problem, and the CropLife figure is the bill the whole category is paying for that. Third, read the cap table. A European life sciences investor leads and a restaurant group's venture arm sits beside it, which is the shape of a round where the downstream buyer is underwriting the agronomy. If your product changes what a food company can say about its supply chain, that company's balance sheet belongs on your fundraising map well before an input industry strategic does.
